Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AVANAFIL vs ATMEKSI
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Selective inhibitor of phosphodiesterase type 5 (PDE5), enhancing nitric oxide-mediated relaxation of smooth muscle in the corpus cavernosum, increasing c GMP levels, and promoting penile erection.
ATMEKSI (atazanavir/cobicistat) is a fixed-dose combination of atazanavir, an HIV-1 protease inhibitor that inhibits viral protease, preventing cleavage of viral polyproteins and resulting in immature non-infectious virions, and cobicistat, a pharmacokinetic enhancer that inhibits CYP3A, increasing atazanavir exposure.
Treatment of erectile dysfunction (FDA-approved),Pulmonary arterial hypertension (off-label)
Treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg,Off-label use as part of antiretroviral therapy in treatment-experienced patients with viral suppression
100 mg orally once daily, taken 30-60 minutes before sexual activity. Maximum dosing frequency: once daily.
1.5 mg/kg IV every 4 weeks
Terminal elimination half-life approximately 6-8 hours. Clinical context: Supports once-daily dosing; steady-state reached within 5 days with no accumulation at FDA-approved dose.
Terminal elimination half-life is 12 hours; renally impaired patients have prolonged half-life up to 24 hours.
Primarily metabolized by CYP3A4, with minor contributions from CYP2C9 and CYP2C19. Subject to first-pass metabolism.
Atazanavir is metabolized by CYP3A4; cobicistat is metabolized by CYP3A and to a minor extent by CYP2D6.
Primarily hepatic metabolism via CYP3A4 and CYP2C9, with metabolites excreted in feces (approximately 82-90%) and urine (approximately 6-8% as unchanged drug and minor metabolites).
Primarily renal (80% unchanged) and biliary/fecal (15% as metabolites).
Approximately 99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
95% bound to albumin and alpha-1-acid glycoprotein.
Volume of distribution approximately 200 L (≈ 2.9 L/kg for a 70 kg individual). Clinical meaning: Indicates extensive tissue distribution, with high affinity for genital tissues.
2.0 L/kg, indicating extensive tissue distribution.
Oral bioavailability approximately 15-20% due to extensive first-pass metabolism. Absolute bioavailability not determined in humans; based on animal data.
Oral: 60-70% due to first-pass metabolism.
No dosage adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended for severe renal impairment (Cr Cl <30 m L/min) as safety and efficacy have not been established.
GFR 15-29 m L/min: 1.0 mg/kg IV every 4 weeks; GFR <15 m L/min: not recommended
Child-Pugh Class A and B: No dosage adjustment required. Child-Pugh Class C: Not recommended due to lack of data.
Child-Pugh A: no adjustment; Child-Pugh B: 1.0 mg/kg IV every 4 weeks; Child-Pugh C: not recommended
Not indicated for use in pediatric patients (age <18 years). Safety and efficacy not established.
Age 2-17 years: 1.5 mg/kg IV every 4 weeks; maximum 120 mg per dose
No dosage adjustment required solely based on age. However, consider lower starting dose (50 mg) in patients ≥65 years due to potential increased sensitivity and decreased clearance.
No specific adjustment; monitor renal function and reduce dose if GFR <30 m L/min
None.
None
Cardiovascular risk: Not recommended in patients with unstable angina, recent MI (within 90 days), or uncontrolled arrhythmias.,Hypotension: Caution with alpha-blockers or antihypertensives; avoid in those with hypotension (BP <90/50 mm Hg).,Priapism: Advise patients to seek immediate medical attention for erections lasting >4 hours.,Hepatic impairment: Avoid use in severe hepatic impairment (Child-Pugh class C).,Renal impairment: Not recommended in patients on renal dialysis.,Visual effects: Non-arteritic anterior ischemic optic neuropathy (NAION) reported, though rare.
Hepatotoxicity, especially in patients with pre-existing liver disease or elevated transaminases,Nephrolithiasis and cholelithiasis,Cardiac conduction abnormalities (PR interval prolongation),Risk of developing resistance if not used with other antiretrovirals,Renal impairment (cobicistat decreases estimated creatinine clearance)
Concomitant use of organic nitrates (e.g., nitroglycerin, isosorbide mononitrate/dinitrate),Concomitant use of guanylate cyclase stimulators (e.g., riociguat),Hypersensitivity to avanafil or any component of the formulation,Severe hepatic impairment (Child-Pugh class C),Recent stroke or myocardial infarction (within 6 months),Patients with hypotension (BP <90/50 mm Hg)
Concomitant use with drugs highly dependent on CYP3A for clearance (e.g., alfuzosin, rifampin, ergot derivatives, St. John's wort, lovastatin, simvastatin, sildenafil for pulmonary arterial hypertension),Severe hepatic impairment (Child-Pugh Class B or C)
Avanafil can be taken with or without food. However, a high-fat meal may delay absorption and reduce peak plasma concentration, potentially prolonging time to onset. Grapefruit juice may increase avanafil levels; avoid concurrent consumption.
Avoid alcohol (may exacerbate CNS effects). Grapefruit juice may increase atomoxetine exposure; limit consumption. High-fat meals do not significantly affect absorption.
No adequate and well-controlled studies in pregnant women. Animal studies show no evidence of teratogenicity at exposures up to 18 times the MRHD. Risk cannot be ruled out; use only if clearly needed.
First trimester: Limited human data; animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: No known fetal risks. Avoid use during organogenesis unless benefit outweighs risk.
Not known if excreted in human milk. No data on M/P ratio. Caution advised; consider developmental benefits of breastfeeding vs potential adverse effects.
Not recommended during breastfeeding. M/P ratio unknown. Excreted in animal milk; potential for serious adverse reactions in nursing infants.
No specific dose adjustments established; use lowest effective dose if indicated. Pharmacokinetic changes in pregnancy unknown; monitor for efficacy and adverse effects.
No dose adjustment required in pregnancy. Pharmacokinetic profile unchanged.
Avanafil is a rapid-onset PDE5 inhibitor with a Tmax of 30-45 minutes, making it suitable for on-demand use. It has minimal interaction with alpha-blockers compared to other PDE5 inhibitors, but caution is still advised. Avoid use in patients taking nitrates or those with severe hepatic impairment (Child-Pugh C). Its short half-life (5 hours) reduces the duration of side effects like headache and flushing.
ATMEKSI (atomoxetine) is a selective norepinephrine reuptake inhibitor (NRI) indicated for ADHD. It has a slower onset of action (2-4 weeks) compared to stimulants. Monitor for hepatotoxicity and suicidal ideation, especially in children and adolescents. Use cautiously with hepatic impairment (reduce dose) and CYP2D6 poor metabolizers (need lower dose). Avoid concurrent MAOIs. May cause orthostatic hypotension and urinary retention.
Take avanafil approximately 30 minutes before sexual activity, with or without food.,Do not take more than one dose in a 24-hour period.,Seek emergency medical attention if you experience an erection lasting more than 4 hours (priapism) or sudden vision loss.,Avoid alcohol or limit to small amounts as it may increase side effects like dizziness or hypotension.,Inform your doctor if you are taking any medications, especially nitrates, alpha-blockers, or antihypertensives.
Take ATMEKSI exactly as prescribed; do not change dose without consulting your doctor.,It may take 2-4 weeks to notice improvement in symptoms.,Avoid alcohol and grapefruit juice as they may affect drug levels.,Report any signs of liver problems (yellowing of skin/eyes, dark urine, abdominal pain) or suicidal thoughts immediately.,May cause dizziness or fainting, especially when standing up; rise slowly.,Do not stop abruptly without medical advice.
"Avanafil, a phosphodiesterase type 5 (PDE5) inhibitor, enhances the vasodilatory effects of nitric oxide by increasing cyclic guanosine monophosphate (cGMP) levels. Acebutolol, a cardioselective beta-blocker, reduces cardiac output and sympathetic outflow. Concurrent use may lead to additive hypotension, particularly during initiation or dose escalation, potentially causing dizziness, syncope, or orthostatic hypotension."
"Cobicistat is a potent inhibitor of CYP3A4, the primary enzyme responsible for metabolizing avanafil. Co-administration significantly increases avanafil's systemic exposure, potentially doubling its plasma concentration and half-life. This elevated exposure raises the risk of avanafil-associated adverse effects, such as hypotension, priapism, and visual disturbances, and may also enhance cobicistat's own serum levels due to shared metabolic pathways, increasing the likelihood of nephrotoxicity and other protease inhibitor-related toxicities."
"Isavuconazonium is a prodrug of isavuconazole, a triazole antifungal that inhibits CYP3A4 and CYP3A5. Coadministration with avanafil, a PDE5 inhibitor metabolized primarily by CYP3A4, can increase avanafil exposure due to reduced clearance. This may elevate the risk of avanafil-associated adverse effects such as hypotension, priapism, and visual disturbances."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AVANAFIL vs ATMEKSI, answered by our medical review team.
AVANAFIL is a PDE5 Inhibitor that works by Selective inhibitor of phosphodiesterase type 5 (PDE5), enhancing nitric oxide-mediated relaxation of smooth muscle in the corpus cavernosum, increasing c GMP levels, and promoting penile erection.. ATMEKSI is a PDE5 Inhibitor that works by ATMEKSI (atazanavir/cobicistat) is a fixed-dose combination of atazanavir, an HIV-1 protease inhibitor that inhibits viral protease, preventing cleavage of viral polyproteins and resulting in immature non-infectious virions, and cobicistat, a pharmacokinetic enhancer that inhibits CYP3A, increasing atazanavir exposure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AVANAFIL and ATMEKSI depend on the specific clinical indication. These are both PDE5 Inhibitor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AVANAFIL is: 100 mg orally once daily, taken 30-60 minutes before sexual activity. Maximum dosing frequency: once daily.. The standard adult dose of ATMEKSI is: 1.5 mg/kg IV every 4 weeks. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AVANAFIL and ATMEKSI in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AVANAFIL is classified as Category C. No adequate and well-controlled studies in pregnant women. Animal studies show no evidence of teratogenicity at exposures up to 18 times the MRHD. Risk cannot be ruled out; use onl. ATMEKSI is classified as Category C. First trimester: Limited human data; animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: No known fetal risks. Avoid use during organogenesis u. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.